Venlafaxine Safety and Efficacy in Adolescents

Safety Concerns

The UK Medicine and Healthcare Products Regulatory Agency (MHRA) concluded that venlafaxine showed an increase in harmful outcomes, including hostility, suicidal ideation, and self-harm in pediatric trials 1, 2, 3
Venlafaxine was among the most intolerable antidepressants in adolescents, with adverse effects including nausea, headaches, and behavioral activation 4

The American Academy of Pediatrics recommends fluoxetine as the preferred first-line antidepressant for adolescent depression, as it is FDA-approved for children aged 8 years and older and has robust evidence for safety and efficacy 4, 5
Escitalopram is FDA-approved for adolescents aged 12-17 years with depression and demonstrated significant improvement compared to placebo in this age group 5
Selective serotonin reuptake inhibitors (SSRIs) are preferred over venlafaxine due to superior efficacy, lower toxicity in overdose, and better tolerability profiles 5